Novavax Announces Changes to Board of Directors

Core Insights - Dr. Young will resign from Novavax's board effective March 10, 2025, after serving since 2010 and as Chair since 2011, during which he guided significant acquisitions and the commercialization of the COVID-19 vaccine [1] - The company is transitioning leadership to Margie McGlynn, who has extensive experience in the vaccine sector, and John C. Jacobs, the current CEO, emphasizing a strong foundation for future growth [2] - Novavax's growth strategy focuses on building diversified partnerships and out-licensing its technology platform and vaccine assets, aiming to expand its early-stage pipeline [4] Leadership Transition - Dr. Young's leadership was pivotal in establishing Novavax's strategic direction, including partnerships and the development of its technology platform [1][2] - Margie McGlynn, with a background in vaccine development and leadership roles, is expected to drive the company's corporate growth strategy [2][3] - The board's collective experience is seen as a strength for advancing Novavax's objectives [2] Company Strategy - Novavax aims to tackle significant health challenges through its innovative vaccine technology, including the Matrix-M™ adjuvant [4] - The company is focusing on strategic collaborations to enhance its research and development capabilities and expand into new disease areas [4] - Investments in an early-stage pipeline are central to Novavax's strategy, leveraging its expertise in infectious diseases [4]